Drug Search Results
More Filters [+]

Panobinostat

Alternative Names: panobinostat, lbh589, farydak, lbh 589, LBH589B, LBH-589B
Latest Update: 2024-02-15
Latest Update Note: Clinical Trial Update

Product Description

Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the FDA and EMA for use in combination with bortezomib and dexamethasone in patients with multiple myeloma who have received ≥2 prior regimens, including bortezomib and an immunomodulatory drug. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26362997/)

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Chile | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Italy | Japan | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States

Approved Indications: Multiple Myeloma

Known Adverse Events: Gastrointestinal Hemorrhage | Anemia | Leukopenia | Lymphopenia | Thrombocytopenia | Neutropenia | Hypokalemia | Hyponatremia | Hypophosphatemia | Pregnancy Outcomes | Pulmonary Edema | Diarrhea | Edema

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Panobinostat

Countries in Clinic: Germany, Korea, Netherlands, Spain, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Multiple Myeloma

Phase 1: Adenocarcinoma|Colorectal Cancer|Kidney Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LBH589

P1

Completed

Kidney Cancer|Adenocarcinoma|Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Renal Cell Carcinoma

2022-02-22

44%

LBH589

P1

Completed

Kidney Cancer|Adenocarcinoma|Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Renal Cell Carcinoma

2022-02-22

44%

2015-001564-19

P2

Active, not recruiting

Multiple Myeloma

2021-10-26

Recent News Events